A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

Shengxiang Ren,Jie Zhang,Yanqiu Zhao,Xiaoqian Mu,Jianying Zhou,Zhang Bao,Yun Fan,Yanjun Xu,Yongqian Shu,Renhua Guo,Xiaoqing Liu,Hong Wang,Helong Zhang,Lin Deng,Ningqiang Ma,Jianxing He,Yalei Zhang,Caicun Zhou,Shanghai Junshi Biosciences

A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

2020

Shengxiang Ren
Jie Zhang
Yanqiu Zhao
Xiaoqian Mu
Jianying Zhou
Zhang Bao
Yun Fan
Yanjun Xu
Yongqian Shu
Renhua Guo
Xiaoqing Liu
Hong Wang
Helong Zhang
Lin Deng
Ningqiang Ma
Jianxing He
Yalei Zhang
Caicun Zhou
Shanghai Junshi Biosciences

e21618Background: Immune checkpoint blocker (ICB) monotherapy showed a lack of response in advanced NSCLC patients with EGFR mutations. This Phase II study aimed to evaluate the efficacy and safety...

Keywords:

Oncology
Internal medicine
egfr tkis
Chemotherapy
Biomarker Analysis
Pathology
in patient
Phases of clinical research
Medicine
Mutant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations